Researchers at Mbarara University of Science and Technology (MUST) are creating a herbal supplement to support immunity among people living with HIV. The product, initially called Moatem Capsules, is being rebranded as Novimunol as the research team prepares to submit it to the National Drug Authority (NDA) for regulatory assessment. This innovation builds on doctoral research conducted in 2017 that examined the potential benefits of combining medicinal plants with antiretroviral medicines.
The herbal supplement is being developed to address challenges faced by people living with HIV, including weakened immunity and complications associated with long-term treatment. According to Dr Jimmy Ronald Angupale, Head of Product Development at MUST’s Pharm-Biotechnology and Traditional Medicine Centre (PHARMBIOTRAC), research findings suggest the herbal combination could improve immunity without interfering with the effectiveness of antiretroviral therapy (ART) when taken as a supplement.
The proposed supplement is based on a combination of two medicinal plants. However, further work is needed to standardise the formulation by identifying and measuring its active compounds. This process will help researchers establish appropriate dosages and assess the product’s safety and quality. The team is also refining the formulation into capsules and tablets to improve stability and make it easier to administer than liquid preparations.
Dr Angupale called for increased and sustained government funding for scientific research, particularly in universities. He said inadequate financing continues to limit the development and commercialisation of locally developed innovations. The research team is expected to submit the supplement to the NDA for assessment before it can be considered for wider use.
The development of the herbal supplement is part of a broader effort to explore more effective and convenient HIV prevention and treatment options. Dr Flavia Matovu Kiweewa, Head of Research at the Makerere University-Johns Hopkins University Research Collaboration, urged the government to invest more in HIV research, including studies on the use of Lenacapavir among children.
Researchers are working to refine the formulation and establish its safety and efficacy. The supplement is not yet approved for use and is still undergoing development. Once submitted to the NDA, it will undergo regulatory assessment before it can be considered for wider use.
The MUST researchers' innovation has the potential to improve the lives of people living with HIV. The supplement's development and potential approval could provide a new option for boosting immunity and managing the challenges associated with HIV treatment. Key points include the supplement's potential to improve immunity without interfering with ART, the need for standardisation and regulatory approval, and the call for increased government funding for scientific research.
Key points
- The herbal supplement is expected to improve immunity among people living with HIV without interfering with antiretroviral therapy.
- The product is still undergoing development and has not yet received regulatory approval.
- Researchers are calling for increased government funding for scientific research to support the development and commercialisation of locally developed innovations.